| Status | Study |
| Completed |
Study Name: An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Condition: Orphan Cholestatic Liver Diseases Progressive Familial Intrahepatic Cholestasis Date: 2017-02-27 Interventions: Drug: 3 mg [14C]-A4250 capsule Each subject will receive a single administration of 3 mg [14C]-A4250 cap |
| Completed |
Study Name: A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Condition: Orphan Cholestatic Liver Diseases Primary Biliary Cirrhosis Date: 2016-11-01 Interventions: Drug: A4250 Drug: CRC (A3384) |
| Enrolling by invitation |
Study Name: FibroScan™ in Pediatric Cholestatic Liver Disease Study Protocol Condition: Biliary Atresia Alagille Syndrome Date: 2016-09-20 Interventions: Other: Liver Stiffness Measurement (LSM) LSM will be measured via transient elastography utilizing the n |
| Active, not recruiting |
Study Name: A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome Condition: Alagille Syndrome Date: 2014-06-09 Interventions: Drug: LUM001 LUM001 administer |
| Completed |
Study Name: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease Condition: Alagille Syndrome Progressive Familial Intrahepatic Cholestasis Date: 2014-05-01 |
| Active, not recruiting |
Study Name: An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome Condition: Alagille Syndrome Date: 2014-04-16 Interventions: Drug: LUM001 Administered orally daily |
| Completed |
Study Name: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Condition: Alagille Syndrome Date: 2014-02-05 Interventions: Drug: LUM001 LUM001 administer |
| Active, not recruiting |
Study Name: An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) Condition: Alagille Syndrome Date: 2014-01-23 Interventions: Drug: LUM001 Dosing of LUM001 with the objective of achieving optimal control of pruritus at a dose leve |
| Completed |
Study Name: Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome Condition: Alagille Syndrome Date: 2013-07-16 Interventions: Drug: LUM001 Drug: Placebo |
| Recruiting |
Study Name: Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review Condition: Alagille Syndrome Date: 2012-01-18 |